Materiality
72
m&a
Source
External coverage
Decided
2026-07-25
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
View event details3 more curated
PSNL
PersonalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Curated Events
4
Active
Recent Headlines
0
New
Recent news sentiment
+72.0
30-day score
Company
-
30-day
Macro
-
30-day
Pulse
-
30-day
Weekly research
-
10-day
Curated events
Sentiment decomposition
+72.0
30-day score
Company-55%
Macro-30%
Pulse-15%
Weekly research-10-day
Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.
Recent headlines
No supplemental ticker headlines stored yet
We are still collecting relevant articles for PSNL. Curated events highlight the most material developments impacting this ticker right now.
As of 2026-07-25 • Updated scheduledSource: News desk